Technical analysis of Neurogene Inc. (NGNE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Price Performance
| 1 month | -5.02% |
| 3 months | +7.45% |
| Year-to-date | +64.47% |
| 1 year | +91.30% |
| 3 years | +120.00% |
| 5 years | -79.44% |
52-Week Range
| 52-week High | $43.66 |
| 52-week Low | $15.93 |
| Avg Volume (90d) | 208K |
Technical Indicators
| SMA 50 | $36.73 |
| SMA 200 | $26.66 |
| Beta | 1.89 |
| 30-day Volatility (annualised) | 52.8% |
| Price vs SMA 50 | -7.8% |
| Price vs SMA 200 | +27.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $34.26 | |
| 2025-11 | $21.08 | -38.5% |
| 2025-12 | $20.60 | -2.3% |
| 2026-01 | $17.66 | -14.3% |
| 2026-02 | $23.49 | +33.0% |
| 2026-03 | $20.16 | -14.2% |
| 2026-04 | $26.09 | +29.4% |
| 2026-05 | $28.34 | +8.6% |
| 2026-06 | $31.45 | +11.0% |
| 2026-07 | $32.89 | +4.6% |
| 2026-08 | $36.24 | +10.2% |
| 2026-09 | $33.88 | -6.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
| 2026-09-14 | $-0.03 | $261M |
| 2026-09-14 | | $1M |
| 2026-09-14 | | |
Price
| Price | $34.67 |
| Market Cap | $548M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.58 |
| EV / EBITDA | -4.69 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 10.64 |